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In our protocol, patients are all studied at home 
with a combination of questionnaire response and 
peak flow measurements taken 3 times daily before 
and after the bronchodilator. The regime we use is as 
follows: 
Week One -Normal therapy; 
Week Two -Salbutamol via Spacer; 
Week Three-Salbutamol via Nebulizer; 
Week Four -1pratropium bromide via Spacer; 
Week five -1pratropium bromide via Nebulizer; 
Week Six -1pratropium bromide and Salbutamol 
via Nebulizer. 
This is sometimes varied with reference to the 
patients individual problems. Patient compliance 
with this procedure is good and the home visits give 
the specialist nurses the opportunity to cover many 
other aspects of education and advice about manage- 
ment of their condition; regular contact continues to 
be made after the trial is completed. 
Referrals for such assessments are mainly from the 
Chest Physician. Other consultants in the hospital 
and general practitioners can also refer, but guide- 
lines sent out by the local Chest Consultant make it 
clear that adult patients severe enough to be consid- 
ered for nebulizer therapy should ideally be assessed 
at the hospital, although not necessarily followed-up 
there. 
During the 3 yr audit period of 1990-1993, there 
were a total of 80 nebulizer trials undertaken. Of 
these, 30% had improved using a nebulizer with 
salbutamol, 4% improved with nebulizer with 
salbutamol and ipratropium bromide, 22% improved 
with salbutamol by large volume spacer and 9% 
showed an inconclusive result. The rest felt that 
conventional inhaled dosage was just as good as any 
of the others. 
We would entirely endorse the conclusions of Hall 
et al. (1) that a nebulizer service run totally by a 
respiratory nurse specialist team is not only feasible, 
but desirable. We think that it is also efficient not 
only in ensuring patients are on the right treatment, 
but in also avoiding unnecessary expensive provision 
of nebulizer compressors where they are not useful. 
P. MCINTYRE, L. ATTFIELD, C. HUMPHERSON, 
B. BRADFORD AND R. DENT 
Queen Elizabeth ZZ Hospital 
Welwyn Garden City, U.X 
22 September 1994 
Reference 
1. Hall IP, Callow IM, Evans SA, Johnston IDA. Audit of 
a complete home nebulizer service provided by a respir- 
atory nurse specialist. Respir Med 1994; 88: 429433. 
Dear Editor 
‘Ethnic discounting’ and spirometry 
In their recommendations concerning the measure- 
ment of respiratory function, the BTSlARTP (1) has 
suggested that prediction of FEV, and FVC in indi- 
viduals of African descent may be made more accu- 
rate by discounting 10% from values derived from 
ECCS reference equations (2). With our hetero- 
geneous population in South Africa, we have had 
sufFicient reason to thoroughly evaluate the useful- 
ness of similar recommendations. I believe that 
ethnic discounting contributes nothing useful to the 
accuracy of predictions. 
Any clinician seeking greater accuracy in predict- 
ing an individual’s lung function could, with equal 
authority, enquire after the individual’s birth weight, 
parental socio-economic status, maternal smoking or 
other known determinants of adult spirometry. If 
African ethnic origin is still going to be accounted 
for, then it is useful to know that significant variation 
in observed normal spirometry has been reported 
between African populations (3). Highest values have 
been reported from countries at higher altitudes such 
as Ethiopia and South Africa. Lower values have 
been reported from West Africa and the Caribbean. 
More recent studies have reported higher values, 
possibly as a consequence of secular trends. Although 
values reported from European populations are 
generally higher, there is considerable overlap in 
the values reported from African and European 
populations. 
Interestingly the BTS recommendations represent 
a change from usual previous practice in the U.K. In 
a questionnaire survey conducted in 1990, respon- 
dents at university-affiliated pulmonary function 
laboratories (PFL) were asked how they would pre- 
dict spirometry in clients of African ancestry (4). 
From the U.K., 10 out of 13 PFL replied that they 
would use reference equations based on a study 
carried out more than 20 yr ago in the Caribbean (5). 
From France, 10 out of 11 PFL replied that they 
would use the ECCS prediction equations without 
any correction factors. At that time ethnic discount- 
ing appeared to be an American practice. Eighteen 
out of 35 U.S.A. PFL stated that they would usually 
apply correction factors to their reference equations. 
Sixteen respondents from the U.S.A. would not apply 
a correction factor, and 1 PFL used an ethnically- 
specific prediction equation. 
Usual U.K. practices for predicting spirometry in 
Africans may be in need of an update. Given the 
variety of possible choices on what to recommend, it 
would be interesting to know why the BTS/ARTP 
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specifically chose to recommend a 10% discount on 
ECCS values. Is this a ‘rule of thumb’, a repetition of 
long-established but poorly substantiated dogma? 
What was the empirical basis of the recommendation. 
In reviewing literature related to this subject, I have 
found little recent published information on spirom- 
etry or anthropometric studies of U.K. immigrants 
who trace their ancestry to Africa. Have there 
been secular effects such as those observed among 
Japanese immigrants into Hawaii (6)? 
Prediction of lung function in Africans may seem a 
subject of relatively minor importance in the U.K., 
but it is important to remember that recommenda- 
tions from prestigious bodies such as the BTS/ARTP 
could be uncritically or over-literally interpreted 
in other countries. In our own PFL, servicing an 
ethnically heterogeneous population, we have chosen 
to use uncorrected ECCS reference equations for 
everyone. This has proven to be perfectly adequate 
for usual clinical purposes. 
N. W. WHITE 
Respiratory Clinic 
Department of Medicine 
University of Cape Town 
Groote Schuur Hospital 
South Africa 7925 
26 September 1994 
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Dear Editor 
The time-table of tuberculosis 
In their Editorial in the August edition of Respir- 
atory Medicine, Rubilar et aZ. (1) state the need to 
extend the often cited ‘time-table of tuberculosis’ 
of Wallgren (2) in the U.K. and other countries 
where most patients are adults with reactivation 
disease. 
At the present time, about one-half of the tubercu- 
losis patients in Southeast England are from ethnic 
minorities, the great majority being of Indian sub- 
continent (ISC) origin. The ISC patients differ from 
white patients in several respects. They tend to be 
much younger (median 34 years) than white patients 
(median 55 years), and non-respiratory forms of 
tuberculosis occur relatively more frequently, with 
the exception of genito-urinary (GU) disease 
which occurs less frequently (3,4). We have therefore 
evaluated these ethnic differences in the light of 
Wallgren’s time-table by examining the data on 
4093 and 3567 isolates of M. tuberculosis from 
patients with European and ISC names, respectively, 
submitted to the PHLS Regional Centre for 
Tuberculosis Bacteriology, Dulwich, between 
1984-1991 (3). 
The numbers of patients with meningitis, dissemi- 
nated disease, which is now often HIV-related in this 
region (3), and pleural effusion were too small to 
permit a meaningful statistical analysis. Lymphatic 
tuberculosis was common, particularly in the ISC 
group, but was not mentioned by Wallgren. There- 
fore we have considered pulmonary, skeletal and GU 
tuberculosis. 
Wallgren’s fourth stage, lasting between l-3 yr 
after primary infection, is characterized by skeletal 
and post-primary pulmonary lesions. The incidence 
of skeletal tuberculosis was much higher in the ISC 
group (8.6% of cases) than in the European group 
(3.5% of cases; P<O.OOl) and this trend was very 
similar in all age groups. The median ages of ISC 
patients with pulmonary and skeletal tuberculosis 
were 33 years and 35 years respectively. The prox- 
imity of ages of those with pulmonary and skeletal 
disease suggests that some of the ISC patients are in 
Wallgren’s fourth stage. This stage precedes that of 
GU tuberculosis which was not analysed by Wallgren 
as he had very few such patients, but was shown by 
Ustvedt (5) to mainly occur 610 yr after the primary 
infection. In our series, GU tuberculosis in the ISC 
population occurred in a significantly older group 
(median 42.5 years; P<O.OOl). As these patients are, 
on average, 8-10 yr older than those with the other 
forms of the disease, this accords well with the 
sequence described by Ustvedt. 
The pattern of age distributions of the different 
types of tuberculosis in the European group was 
substantially different. The median ages of patients 
with pulmonary and GU tuberculosis were similar, 
